Predictive Value of Procalcitonin for Bacterial Infection After Transarterial Chemoembolization or Radiofrequency Ablation for Hepatocellular Carcinoma

Overview

Journal Dis Markers

Publisher Wiley

Specialty Biochemistry

Date 2018 Jun 1

PMID 29849829

Citations 4

Authors

Seung Ji Kang

Uh Jin Kim

Seong Eun Kim

Joon Hwan An

Mi Ok Jang

Dae-Seong Myung

Kyung-Hwa Park

Sook-In Jung

Sung Bum Cho

Hee-Chang Jang

Young Eun Joo

Affiliations

Soon will be listed here.

Abstract

This prospective observational study aimed at investigating the role of procalcitonin (PCT) in diagnosing bacterial infection and guiding antibiotic therapy for hepatocellular carcinoma (HCC) patients with fever after transarterial chemoembolization (TACE) and/or radiofrequency ablation (RFA). Ninety-seven cases (84 patients) were enrolled. Serum PCT, C-reactive protein (CRP), and white blood cell (WBC) counts were measured on the day of fever onset (day 0) and days 1, 3, 5, and 7 of fever. Empirical antibiotics were initiated only if PCT was ≥0.5 ng/mL or specific infection foci were suspected. An infectious cause was found in nine cases. PCT on day 0 of fever was significantly higher in patients with bacterial infection than in those without infection ( = 0.035). The area under the receiver operating characteristic curve for PCT was 0.715 (95% confidence interval, 0.538-0.892) and was higher than that for CRP (0.598 (0.368-0.828)) or WBC counts (0.502 (0.307-0.697)). In patients undergoing TACE and/or RFA, a significantly lower number of antibiotics were prescribed during the study period than during the prestudy period ( < 0.001). In conclusion, PCT might be a biomarker for diagnosing infection and guiding antibiotic treatment to reduce unnecessary antibiotic use in patients with fever after TACE and/or RFA.

Citing Articles

Bacterial infections and fever after hepatocellular carcinoma ablation therapy: Predictive role of procalcitonin.

Abdelkader A, Abdelkhalek R, Hosny H, Emara M, Elshamy M Clin Exp Hepatol. 2023; 9(2):122-128.

PMID: 37502430 PMC: 10369656. DOI: 10.5114/ceh.2023.127400.

Evaluating the Benefits of TACE Combined with Lenvatinib Plus PD-1 Inhibitor for Hepatocellular Carcinoma with Portal Vein Tumor Thrombus.

Zou X, Xu Q, You R, Yin G Adv Ther. 2023; 40(4):1686-1704.

PMID: 36805422 DOI: 10.1007/s12325-023-02449-6.

Prophylactic Use of Antibiotics for Postsurgical Infection in c-TACE and DEB-TACE High-Risk Patients: A Case-Control Study.

Li B J Healthc Eng. 2022; 2022:6203817.

PMID: 35444783 PMC: 9015880. DOI: 10.1155/2022/6203817.

Safety assessment of cosmetics by read across applied to metabolomics data of in vitro skin and liver models.

Jacques C, Jamin E, Jouanin I, Canlet C, Tremblay-Franco M, Martin J Arch Toxicol. 2021; 95(10):3303-3322.

PMID: 34459931 DOI: 10.1007/s00204-021-03136-7.

References

Brown D, Gould J, Gervais D, Goldberg S, Murthy R, Millward S . Transcatheter therapy for hepatic malignancy: standardization of terminology and reporting criteria. J Vasc Interv Radiol. 2007; 18(12):1469-78. DOI: 10.1016/j.jvir.2007.08.027. View

Leli C, Ferranti M, Moretti A, Al Dhahab Z, Cenci E, Mencacci A . Procalcitonin levels in gram-positive, gram-negative, and fungal bloodstream infections. Dis Markers. 2015; 2015:701480. PMC: 4380090. DOI: 10.1155/2015/701480. View

Gaba R, Lokken R, Hickey R, Lipnik A, Lewandowski R, Salem R . Quality Improvement Guidelines for Transarterial Chemoembolization and Embolization of Hepatic Malignancy. J Vasc Interv Radiol. 2017; 28(9):1210-1223.e3. DOI: 10.1016/j.jvir.2017.04.025. View

Lee H . Procalcitonin as a biomarker of infectious diseases. Korean J Intern Med. 2013; 28(3):285-91. PMC: 3654123. DOI: 10.3904/kjim.2013.28.3.285. View

Schuetz P, Albrich W, Mueller B . Procalcitonin for diagnosis of infection and guide to antibiotic decisions: past, present and future. BMC Med. 2011; 9:107. PMC: 3186747. DOI: 10.1186/1741-7015-9-107. View

Marciano S, Haddad L, Martinez A, Posadas M, Pinero F, Mora G . Ultra-sensitive procalcitonin may help rule out bacterial infections in patients with cirrhosis. Ann Hepatol. 2014; 13(5):541-7. View

Conti F, DallAgata M, Gramenzi A, Biselli M . Biomarkers for the early diagnosis of bacterial infection and the surveillance of hepatocellular carcinoma in cirrhosis. Biomark Med. 2015; 9(12):1343-51. DOI: 10.2217/bmm.15.100. View

Connert S, Stremmel W, Elsing C . Procalcitonin is a valid marker of infection in decompensated cirrhosis. Z Gastroenterol. 2003; 41(2):165-70. DOI: 10.1055/s-2003-37314. View

Dhainaut J, Claessens Y, Janes J, Nelson D . Underlying disorders and their impact on the host response to infection. Clin Infect Dis. 2005; 41 Suppl 7:S481-9. DOI: 10.1086/432001. View

10.

Filippousis P, Sotiropoulou E, Manataki A, Konstantinopoulos O, Thanos L . Radiofrequency ablation of subcapsular hepatocellular carcinoma: single center experience. Eur J Radiol. 2009; 77(2):299-304. DOI: 10.1016/j.ejrad.2009.07.003. View

11.

Dabbous H, Ali-Eldin F, Montasser I . Role of procalcitonin in diagnosis of bacterial infection in trans-arterial chemoembolisation treated hepatocellular carcinoma patients. Arab J Gastroenterol. 2015; 16(1):10-3. DOI: 10.1016/j.ajg.2015.03.001. View

12.

Bruix J, Sherman M, Llovet J, Beaugrand M, Lencioni R, Burroughs A . Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol. 2001; 35(3):421-30. DOI: 10.1016/s0168-8278(01)00130-1. View

13.

Delevaux I, Andre M, Colombier M, Albuisson E, Meylheuc F, Begue R . Can procalcitonin measurement help in differentiating between bacterial infection and other kinds of inflammatory processes?. Ann Rheum Dis. 2003; 62(4):337-40. PMC: 1754509. DOI: 10.1136/ard.62.4.337. View

14.

Li C, Chao Y, Chen L, Lee R, Lee W, Yuan J . Fever after transcatheter arterial chemoembolization for hepatocellular carcinoma: incidence and risk factor analysis. Scand J Gastroenterol. 2008; 43(8):992-9. DOI: 10.1080/00365520801971744. View

15.

Hoeboer S, van der Geest P, Nieboer D, Groeneveld A . The diagnostic accuracy of procalcitonin for bacteraemia: a systematic review and meta-analysis. Clin Microbiol Infect. 2015; 21(5):474-81. DOI: 10.1016/j.cmi.2014.12.026. View

16.

Foreman M, Mannino D, Moss M . Cirrhosis as a risk factor for sepsis and death: analysis of the National Hospital Discharge Survey. Chest. 2003; 124(3):1016-20. DOI: 10.1378/chest.124.3.1016. View

17.

Fitzmorris P, Shoreibah M, Anand B, Singal A . Management of hepatocellular carcinoma. J Cancer Res Clin Oncol. 2014; 141(5):861-76. DOI: 10.1007/s00432-014-1806-0. View

18.

Sakamoto I, Aso N, Nagaoki K, Matsuoka Y, Uetani M, Ashizawa K . Complications associated with transcatheter arterial embolization for hepatic tumors. Radiographics. 1998; 18(3):605-19. DOI: 10.1148/radiographics.18.3.9599386. View

19.

Rhim H . Complications of radiofrequency ablation in hepatocellular carcinoma. Abdom Imaging. 2005; 30(4):409-18. DOI: 10.1007/s00261-004-0255-7. View

20.

Ebisutani C, Sato S, Nishi K, Inoue H, Yoshie T, Kinoshita Y . Antibiotic prophylaxis in transcatheter treatment of hepatocellular carcinoma: an open randomized prospective study of oral versus intravenous administration. Intern Med. 2010; 49(12):1059-65. DOI: 10.2169/internalmedicine.49.3173. View